Spectral AIMDAI
MDAI
About: Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
Employees: 78
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
800% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 22 [Q2] → 23 (+1) [Q3]
1.84% more ownership
Funds ownership: 15.68% [Q2] → 17.53% (+1.84%) [Q3]
22% less capital invested
Capital invested by funds: $4.63M [Q2] → $3.6M (-$1.03M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for MDAI.
Financial journalist opinion
Based on 4 articles about MDAI published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Spectral AI Comments on Compliance with Nasdaq Listing Rule 5550(b)(2)
DALLAS, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced today that the Company believes it has regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires listed companies to maintain a minimum market value of listed securities of $35 million.
Neutral
GlobeNewsWire
1 week ago
Spectral AI Incorporates Frontline Feedback into Improved Software Release for Enhanced Diagnostic Precision
DALLAS, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the completion of enhancements to its technical file to support significant software updates for its DeepView SnapShot® M and DeepView AI-Burn® system in the UK. These upgrades, informed by real-world experience and frontline feedback from clinicians, are designed to enhance product performance and usability in the UK, further solidifying the Company's commitment to delivering and commercializing cutting-edge solutions in critical care settings.
Neutral
GlobeNewsWire
2 weeks ago
Spectral AI Completes Truthing of Burn Center Images, Initiates Emergency Department Image Review
DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the successful completion of truthing for all images gathered from burn centers across the United States. This milestone represents a pivotal step in training the Company's proprietary DeepView® System to predict wound healing outcomes accurately. Having completed the process for burn centers, Spectral AI is now initiating truthing for images collected from emergency departments and emergency rooms nationwide, expanding the scope of the DeepView® System's capabilities.
Neutral
GlobeNewsWire
3 weeks ago
Spectral AI Announces Repricing of its Public Warrants
DALLAS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the repricing of its 8,433,333 publicly-traded common share purchase warrants with an exercise price of $11.50 per share to $2.75 per share, effective following its twenty day notice requirement. The warrants currently trade on NASDAQ under the symbol MDAIW.
Neutral
GlobeNewsWire
1 month ago
Spectral AI Raises Up to $5 Million Financing Strengthening Financial Position for FDA Pathway
DALLAS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the successful completion of an approximate $5.0 million equity financing in an at-the-market transaction. The closing is to be completed in two tranches. Part of the proceeds will be used for the retirement of its outstanding obligations with Yorkville Advisors. This transaction supports Spectral AI's growth trajectory and progress toward a submission to the U.S. Food and Drug Administration (“FDA”) for approval of its DeepView AI®-Burn system, a crucial milestone targeted for the first half of 2025.
Neutral
Seeking Alpha
1 month ago
Spectral AI, Inc. (MDAI) Q3 2024 Earnings Conference Call Transcript
Spectral AI, Inc. (NASDAQ:MDAI ) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Devin Sullivan - MD of Equity Group Michael DiMaio - Chairman Vincent Capone - CFO Conference Call Participants Ryan Zimmerman - BTIG Carl Byrnes - Northland Capital Markets RK Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon, and welcome to the Spectral AI Third Quarter 2024 Financial Results Conference Call.
Positive
Proactive Investors
1 month ago
Spectral AI reports strong Q3 performance, reaffirms FDA submission timeline
Spectral AI Inc (NASDAQ:MDAI) reported a strong financial performance for the third quarter of 2024, highlighted by a 138% increase in research and development revenue as it advanced its burn wound technology. For Q3 2024, the company posted $8.2 million in revenue, up from $3.4 million in the same quarter last year.
Neutral
GlobeNewsWire
1 month ago
Spectral AI Announces 2024 Third Quarter Financial Results
Revenue Rose to $8.2 Million Company Reaffirms Timeline for Regulatory Submission to U.S. FDA
Positive
Proactive Investors
1 month ago
Spectral AI to spin off subsidiary to focus on IP monetization, healthcare AI expansion
Spectral AI Inc (NASDAQ:MDAI) announced plans to spin off its subsidiary, Spectral IP, Inc., through a deal with Sauvegarder Investment Management, Inc. (SIM). The transaction aims to position Spectral IP as an independent company with a broader focus on intellectual property (IP) monetization across various sectors, including healthcare, artificial intelligence, and semiconductors.
Neutral
GlobeNewsWire
1 month ago
Spectral AI Announces Plan to Spin Off Spectral IP Subsidiary Focused on Intellectual Property Investments and Monetization
Strategic Spinoff Aims to Unlock IP Value and Sharpen Focus on AI Medical Diagnostics Strategic Spinoff Aims to Unlock IP Value and Sharpen Focus on AI Medical Diagnostics
Charts implemented using Lightweight Charts™